Resources>Webinars>Biointron x NextGen Biomed 2026 Webinar: Accelerating Antibody Discovery

Biointron x NextGen Biomed 2026 Webinar: Accelerating Antibody Discovery

Biointron 2026-03-31

About

Webinar Title: Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform

During the NextGen Biomed 2026 conference in London, Lei Shi, PhD, Senior Vice President of Biointron, discussed Biointron's unique single B cell sorting-based antibody discovery process integrated with our high-throughput expression, validation and developability platforms.

This webinar presents an overview of next-generation antibody discovery using the AbDrop platform, an industrial-scale system designed to overcome the limitations of traditional methods such as hybridoma and phage display.

Attendees are introduced to a high-throughput workflow that enables direct recovery of native, full-length antibodies from plasma B cells. The session outlines how millions of B cells can be screened in a single day, with paired heavy and light chain sequences identified and validated within weeks, significantly accelerating discovery timelines. The webinar also covers the end-to-end process, including droplet-based screening, FRET sorting, next-generation sequencing, and automated expression systems capable of producing thousands of high-purity antibodies per batch.

A featured case study on PD-1 antibody discovery demonstrates the platform’s ability to generate diverse, high-affinity candidates with both blocking and agonistic functions, supported by in vitro and in vivo validation data.

RushData integrates early developability assessment, such as stability, expression, and non-specific binding, into the discovery phase. This enables faster, data-driven decision-making and reduces downstream risk.

Watch the recording here >>

About the Speaker

Lei Shi, PhD. is Senior Vice President of Biointron. He has more than 20 years of experience in antibody discovery. Previously, Lei worked for a number of pharmaceutical and biotech companies such as Johnson & Johnson with increasing responsibilities. He completed his postdoc research at MGH and Harvard Medical School and has an Executive Master's degree from the University of Pennsylvania.

Watch the recording here >>

Recommended Articles
Biointron x Antibody Society Webinar: RushDATA™: Closing the Loop on AI-Designed Antibodies with Rapid Wet-Lab Data

Join The Antibody Society and Biointron for a talk featuring Dr. Brady Wu, Head ……

Oct 30, 2026
Biointron x SelectScience Webinar: Advancing AI-driven antibody discovery through experimental validation with RushDATA™

AI is accelerating antibody design, allowing teams to generate and optimize cand……

Oct 30, 2026
Biointron x Scientist.com Webinar: AI-Ready, Lab-Proven: A New Standard for High-Throughput Antibody Characterization

AI is transforming antibody discovery, but better models only come from better d……

Jul 14, 2026
Biointron x Chinese Antibody Society Webinar: RushData: Delivering Rapid Wet-Lab Data to Close the Loop on AI-Designed Antibodies

The antibody therapeutics sector is rapidly evolving, transitioning from traditi……

Jun 25, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.